Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study (Placebo-Controlled, Double-Blind and Randomized Phase III Study of Intravaginal Prasterone)

NCT03619005 is registered in ClinicalTrials.gov with EndoCeutics Inc. as lead sponsor.

NCT NCT03619005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03619005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study (Placebo-Controlled, Double-Blind and Randomized Phase III Study of Intravaginal Prasterone)
Lead sponsor
EndoCeutics Inc.
Phase
Phase 3
Overall status
Withdrawn
Start date
November 13, 2018
Completion date
December 6, 2019
Enrollment
0 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

hypoactive sexual desire disorder (hsdd)